Chronic Myeloid Leukemia Clinical Trial
Official title:
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
This study involves observing the level of cell cycle regulatory gene in patients with
myeloproliferative disorders(MPD). These disorders include polycythemia vera (PV), essential
thrombocythemia (ET), myelofibrosis (MF) and chronic myeloid leukemia (CML). The abnormal
blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA,
RNA, protein or plasma will be used in laboratory studies.
Cell cycle regulatory protein such as cyclins, cyclin-dependent kinases(Cdks) and Cdk
inhibitors(CKIs) play indispensable roles in processes such as transcription, metabolism and
stem cell self-renewal. MPD are a group of diseases characterized by abnormally increased
proliferation of erythroid, megakaryocytic, or granulocytic cells. The pathogenesis was
still unclear. Detecting the level of cell cycle regulatory protein will be useful to look
for the possible role in MPD and better understand the cause of MPD.
This study involves observing the level of cell cycle regulatory gene in patients with
myeloproliferative disorders(MPD). These disorders include polycythemia vera (PV), essential
thrombocythemia (ET), myelofibrosis (MF) and chronic myeloid leukemia (CML). The abnormal
blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA,
RNA, protein or plasma will be used in laboratory studies.
Cell cycle regulatory protein such as cyclins, cyclin-dependent kinases(Cdks) and Cdk
inhibitors(CKIs) play indispensable roles in processes such as transcription, metabolism and
stem cell self-renewal. MPD are a group of diseases characterized by abnormally increased
proliferation of erythroid, megakaryocytic, or granulocytic cells. The pathogenesis was
still unclear. Detecting the level of cell cycle regulatory protein will be useful to look
for the possible role in MPD and better understand the cause of MPD.
In this study, the cell cycle regulatory message RNA and protein from patients' and healthy
volunteers' bone marrow and peripheral blood will be extracted and quantified by real time
polymerase chain reaction and western blot. The different level of cell cycle regulatory
gene between patients and volunteers and the relationship between the level and patients'
clinical characteristics such as age, gender, type of disease will be analysed by SPSS.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
| Recruiting |
NCT03326310 -
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
|
Phase 1 | |
| Recruiting |
NCT04621851 -
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
|
||
| Completed |
NCT01207440 -
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Active, not recruiting |
NCT02917720 -
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
|
Phase 2 | |
| Not yet recruiting |
NCT02883036 -
Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
|
N/A | |
| Withdrawn |
NCT01188889 -
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
|
Phase 1/Phase 2 | |
| Completed |
NCT01795716 -
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
|
Phase 1 | |
| Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
| Approved for marketing |
NCT00905593 -
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
Phase 3 | |
| Terminated |
NCT00573378 -
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
|
Phase 2 | |
| Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
| Completed |
NCT00469014 -
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
|
Phase 2 | |
| Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
| Completed |
NCT00257647 -
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
|
N/A | |
| Completed |
NCT00219739 -
STI571 ProspectIve RandomIzed Trial: SPIRIT
|
Phase 3 | |
| Completed |
NCT06148493 -
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
|
||
| Completed |
NCT00375219 -
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
|
Phase 2 | |
| Completed |
NCT04605211 -
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
|
N/A |